Zhejiang Medicine Past Earnings Performance
Past criteria checks 4/6
Zhejiang Medicine has been growing earnings at an average annual rate of 3.3%, while the Pharmaceuticals industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 3.1% per year. Zhejiang Medicine's return on equity is 3.4%, and it has net margins of 5.7%.
Key information
3.3%
Earnings growth rate
3.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 3.1% |
| Return on equity | 3.4% |
| Net Margin | 5.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Zhejiang Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 8,262 | 473 | 1,576 | 807 |
| 31 Mar 24 | 8,035 | 426 | 1,501 | 890 |
| 31 Dec 23 | 7,794 | 430 | 1,482 | 860 |
| 30 Sep 23 | 7,868 | 356 | 1,265 | 861 |
| 30 Jun 23 | 7,936 | 421 | 1,335 | 884 |
| 31 Mar 23 | 7,940 | 393 | 1,368 | 803 |
| 31 Dec 22 | 8,116 | 540 | 1,309 | 809 |
| 30 Sep 22 | 8,441 | 779 | 1,438 | 670 |
| 30 Jun 22 | 8,629 | 928 | 1,407 | 617 |
| 31 Mar 22 | 8,913 | 1,039 | 1,476 | 724 |
| 31 Dec 21 | 9,129 | 1,045 | 1,557 | 807 |
| 30 Sep 21 | 8,709 | 847 | 1,561 | 844 |
| 30 Jun 21 | 8,416 | 798 | 1,594 | 881 |
| 31 Mar 21 | 8,127 | 836 | 1,575 | 736 |
| 31 Dec 20 | 7,327 | 717 | 1,521 | 546 |
| 30 Sep 20 | 7,154 | 603 | 1,655 | 610 |
| 30 Jun 20 | 6,987 | 489 | 1,705 | 550 |
| 31 Mar 20 | 6,925 | 358 | 1,863 | 452 |
| 31 Dec 19 | 7,044 | 343 | 1,984 | 450 |
| 30 Sep 19 | 7,073 | 210 | 2,042 | 359 |
| 30 Jun 19 | 7,052 | 177 | 1,989 | 308 |
| 31 Mar 19 | 6,655 | 32 | 1,899 | 336 |
| 31 Dec 18 | 6,859 | 365 | 1,893 | 322 |
| 30 Sep 18 | 6,879 | 636 | 1,750 | 294 |
| 30 Jun 18 | 6,600 | 632 | 1,502 | 382 |
| 31 Mar 18 | 6,426 | 694 | 1,298 | 307 |
| 31 Dec 17 | 5,693 | 253 | 1,017 | 258 |
| 30 Sep 17 | 5,224 | 176 | 862 | 162 |
| 30 Jun 17 | 5,122 | 348 | 813 | 0 |
| 31 Mar 17 | 5,159 | 409 | 801 | 0 |
| 31 Dec 16 | 5,279 | 450 | 768 | 0 |
| 30 Sep 16 | 5,089 | 378 | 722 | 0 |
| 30 Jun 16 | 4,994 | 219 | 732 | 0 |
| 31 Mar 16 | 4,757 | 255 | 674 | 0 |
| 31 Dec 15 | 4,497 | 162 | 675 | 0 |
| 30 Sep 15 | 4,505 | 62 | 675 | 0 |
| 30 Jun 15 | 4,434 | 93 | 685 | 0 |
| 31 Mar 15 | 4,644 | 47 | 693 | 0 |
| 31 Dec 14 | 4,832 | 170 | 685 | 0 |
| 30 Sep 14 | 4,843 | 326 | 669 | 0 |
| 30 Jun 14 | 4,860 | 306 | 669 | 0 |
| 31 Mar 14 | 4,887 | 365 | 650 | 0 |
| 31 Dec 13 | 4,933 | 452 | 633 | 0 |
| 30 Sep 13 | 5,074 | 550 | 636 | 0 |
Quality Earnings: 600216 has a large one-off gain of CN¥216.4M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 600216's current net profit margins (5.7%) are higher than last year (5.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600216's earnings have grown by 3.3% per year over the past 5 years.
Accelerating Growth: 600216's earnings growth over the past year (12.2%) exceeds its 5-year average (3.3% per year).
Earnings vs Industry: 600216 earnings growth over the past year (12.2%) exceeded the Pharmaceuticals industry -0.8%.
Return on Equity
High ROE: 600216's Return on Equity (3.4%) is considered low.